30 completed, 21 terminated, 3 withdrawn, 2 active not recruiting. 56 Phase 2, 7 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 56 | Completed 30, Terminated 21, Withdrawn 3, Active not recruiting 2 |
| Phase 1 | 7 | Terminated 4, Completed 3 |
| Phase 3 | 6 | Completed 4, Terminated 2 |
Follow EMD Serono: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Avelumab and M1774 in ARID1A-mutated Endometrial Cancer Avelumab, M1774 - Endometrial Cancer, ARID1A Gene Mutation | Phase 2 | Active not recruiting | Panagiotis Konstantinopoulos, MD, PhD | 8 | 2024-11-14 | 2026-10-26 |
| Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma Avelumab, Comprehensive Ablative Radiation Therapy - Merkel Cell Carcinoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 18 | 2021-03-08 | 2026-04-07 |
| Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors avelumab, Bempegaldesleukin, talazoparib - Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Terminated | Pfizer | 3 | 2019-12-30 | 2021-10-14 |
| Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer Avelumab, BCG - Bladder Cancer | Phase 1 / Phase 2 | Completed | University of Oklahoma | 18 | 2019-05-01 | 2024-02-14 |
| The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy Avelumab and Radical radiotherapy - Squamous Cell Carcinoma of the Skin | Phase 2 | Terminated | AHS Cancer Control Alberta | 8 | 2019-04-12 | 2025-06-27 |
| Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC Avelumab, 2nd generation ADT (abiraterone or enzalutamide) - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Terminated | Jodi Layton, MD | 8 | 2019-01-25 | 2024-07-09 |
| Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas Oxaliplatin, Leucovorin, 5 fluorouracil - Gastric Adenocarcinoma, Esophageal Adenocarcinoma | Phase 2 | Completed | Ashwin Somasundaram | 18 | 2019-01-24 | 2023-12-19 |
| M6620 (VX-970) in Selected Solid Tumors M6620 - Solid Tumor, Leiomyosarcoma | Phase 2 | Completed | Massachusetts General Hospital | 30 | 2019-01-08 | 2023-07-07 |
| Avelumab and Radiation in Muscle-Invasive Bladder Cancer Avelumab, Radiation - Bladder Cancer, Muscle Invasive Bladder Cancer | Phase 2 | Terminated | Dana-Farber Cancer Institute | 14 | 2018-12-13 | 2025-10-31 |
| A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab PT-112, avelumab - Non-Small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Completed | Promontory Therapeutics Inc. | 68 | 2018-04-24 | 2023-11-18 |
| Avelumab With Valproic Acid in Virus-associated Cancer Valproic Acid, Avelumab - Cancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN | Phase 2 | Completed | AHS Cancer Control Alberta | 39 | 2018-02-07 | 2025-06-26 |
| Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery Avelumab, Trabectedin - Metastatic Leiomyosarcoma, Metastatic Liposarcoma | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 35 | 2017-09-28 | 2022-04-29 |
| Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma Avelumab, Hypofractionated radiation therapy (HFRT) - Glioblastoma | Phase 2 | Completed | NYU Langone Health | 6 | 2017-03-17 | 2022-06-29 |
| Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma Avelumab - Adenocarcinoma | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 8 | 2017-03-03 | 2022-04-14 |
| Impact of Recombinant Human Growth Hormone on HIV Persistence Somatotropin (Human) - Human Immunodeficiency Virus, Growth Hormone Treatment | Phase 2 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 22 | 2016-12-01 | 2025-09-25 |
| Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma Avelumab, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells - Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7 | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 8 | 2015-11-06 | 2022-03-22 |
| Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II) Atacicept 75 mg, Atacicept 150 mg - Lupus Erythematosus, Systemic | Phase 2 | Terminated | EMD Serono | 253 | 2014-07-29 | 2019-03-21 |
| Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer TH-302 combination with pemetrexed, Matched placebo in combination with pemetrexed - Non-small Cell Lung Cancer | Phase 2 | Terminated | ImmunoGenesis | 265 | 2014-06-01 | 2025-05-16 |
| MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma MSB0010445 (0.3 milligram per kilogram [mg/kg]), MSB0010445 (1.0 mg/kg), MSB0010445 (1.8 mg/kg) - Melanoma | Phase 2 | Terminated | EMD Serono | 12 | 2014-01-01 | 2016-10-31 |
| Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus Atacicept 75 milligram (mg), Atacicept 150 mg, Placebo - Lupus Erythematosus, Systemic | Phase 2 | Completed | EMD Serono | 306 | 2013-12-01 | 2018-01-02 |
Showing 20 of 56. Sign in to see all of them.
Glioblastoma (4) · Lupus Erythematosus, Systemic (4) · Carcinoma, Non-Small-Cell Lung (3) · Melanoma (3) · Neoplasm Metastasis (3) · Ovarian Neoplasms (3) · Recurrence (3) · Acquired Immunodeficiency Syndrome (2) · Arthritis, Rheumatoid (2) · Carcinoma, Merkel Cell (2) · Infertility (2) · Leiomyosarcoma (2) · Lung Neoplasms (2) · Multiple Sclerosis (2) · Neoplasms (2)
avelumab (14) · TACI receptor-IgG Fc fragment fusion protein (10) · Growth Hormone (6) · Human Growth Hormone (5) · N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide (4) · Cilengitide (3) · Radiotherapy (3) · Anastrozole (2) · Interferon beta-1a (2) · Pemetrexed (2) · Radiation (2) · enzalutamide (2) · matuzumab (2) · Abituzumab (1) · Adalimumab (1)
United States (42) · Germany (17) · Spain (14) · Canada (13) · United Kingdom (12) · Belgium (11) · Czechia (11) · France (10) · Poland (10) · Russia (9) · Switzerland (8) · Australia (7) · Italy (7) · South Africa (7) · Netherlands (6)
Claudia Pena Rossi, M.D. (2) · Andriy Markivskyy, MD (1) · Arthur Leader, BSc., MD, FRCSC (1) · Ashwin Somasundaram, MD (1) · Aude Chapuis (1) · Christoper Barker, MD (1) · Dana Cardin, M.D. (1) · Daniel D Karp, MD (1) · Daniel Mikol, MD, PhD (1) · Ellen Brady, M.D. MPH (1) · Gregory M Cote, MD, PhD (1) · Jodi L Layton, MD (1) · John Walker, MD PhD FRCPC (1) · John Walker, Walker (1)
PMID 24613349, PMID 37332136, PMID 15076238, PMID 17126894, PMID 18292808, PMID 18292816, PMID 18981465, PMID 19145731, PMID 19302707, PMID 20978446, PMID 21452293, PMID 21452294, PMID 22325903, PMID 24894651, PMID 24951103, PMID 29073347, PMID 29756206, PMID 30073390, PMID 31401903, PMID 32107560, PMID 32152202, PMID 32610581, PMID 33547784, PMID 36210487, PMID 36346112, PMID 36532058, PMID 40571483
2009 (2), P30CA015704 (2), 2019 (1), K24CA139052 (1), R01AI043864 (1), R01CA032685 (1), R01CA176841 (1)